| HeLa |
MCC |
= |
0.4 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures. |
CHEMBL1122581 |
| Vesicular stomatitis virus |
MIC |
= |
0.006999999999999999 |
ug.mL-1 |
Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures. |
CHEMBL1122581 |
| Human coxsackievirus B4 |
MIC |
= |
0.2 |
ug.mL-1 |
Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures. |
CHEMBL1122581 |
| Human poliovirus 1 |
MIC |
= |
0.006999999999999999 |
ug.mL-1 |
Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures. |
CHEMBL1122581 |
| Vero |
MCC |
= |
0.4 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures. |
CHEMBL1122581 |
| Mammalian orthoreovirus 1 |
MIC |
= |
0.07 |
ug.mL-1 |
Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Human parainfluenza virus 3 |
MIC |
= |
0.07 |
ug.mL-1 |
Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Sindbis virus |
MIC |
= |
0.2 |
ug.mL-1 |
Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Human coxsackievirus B4 |
MIC |
= |
0.2 |
ug.mL-1 |
Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Oryctolagus cuniculus |
MCC |
= |
0.4 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Human herpesvirus 1 |
MIC |
= |
0.07 |
ug.mL-1 |
Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Human herpesvirus 2 |
MIC |
= |
0.2 |
ug.mL-1 |
Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Vaccinia virus |
MIC |
= |
0.02 |
ug.mL-1 |
Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Vesicular stomatitis virus |
MIC |
= |
0.006999999999999999 |
ug.mL-1 |
Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| L1210 |
ID50 |
= |
0.04 |
ug ml-1 |
Dose required to inhibit proliferation of L-1210 Cells by 50% |
CHEMBL1122581 |
| Oryctolagus cuniculus |
MTC |
= |
0.4 |
ug ml-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells |
CHEMBL1123899 |
| Human herpesvirus 1 |
MIC50 |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human herpesvirus 2 |
MIC50 |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Vaccinia virus |
MIC50 |
= |
0.006999999999999999 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Vesicular stomatitis virus |
MIC50 |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| HeLa |
MTC |
= |
0.4 |
ug ml-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells |
CHEMBL1123899 |
| Vesicular stomatitis virus |
MIC50 |
= |
0.01 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human coxsackievirus B4 |
MIC50 |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human poliovirus 1 |
MIC50 |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Vero |
MTC |
= |
0.4 |
ug ml-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells |
CHEMBL1123899 |
| Mammalian orthoreovirus 1 |
MIC50 |
= |
0.04 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human parainfluenza virus 3 |
MIC50 |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Sindbis virus |
MIC50 |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human coxsackievirus B4 |
MIC50 |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Measles virus |
MIC50 |
= |
0.3 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity by 50% |
CHEMBL1123899 |
| L1210 |
MIC50 |
= |
0.04 |
ug.mL-1 |
Inhibition of murine leukemia L1210 cell growth |
CHEMBL1123899 |
| L1210 |
MIC50 |
= |
5.4 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce incorporation of [methyl-3H]dThd into TCA-insoluble material from murine leukemia L1210 cells |
CHEMBL1123899 |
| L1210 |
MIC50 |
= |
0.29 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce incorporation of [5-3H]-Urd into TCA-insoluble material from murine leukemia L1210 cells |
CHEMBL1123899 |
| L1210 |
MIC50 |
= |
0.173 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce incorporation of [4,5-3H]leucine into TCA-insoluble material from murine leukemia L1210 cells |
CHEMBL1123899 |
| HEp-2 |
IC50 |
= |
2.0 |
nM |
Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control. |
CHEMBL1122762 |
| HEp-2 |
IC50 |
> |
3000.0 |
nM |
Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control |
CHEMBL1122762 |
| Oryctolagus cuniculus |
MCC |
= |
0.4 |
ug.mL-1 |
Evaluation for antiviral activity in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Human herpesvirus 1 |
MIC |
>= |
0.4 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus type 1 (strain KOS) in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Human herpesvirus 2 |
MIC |
>= |
0.4 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus type 2 (strain G) in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Vaccinia virus |
MIC |
= |
0.07 |
ug.mL-1 |
Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Vesicular stomatitis virus |
MIC |
= |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against vesion stomatitis virus in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Oryctolagus cuniculus |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in primary rabbit kidney (PRK) cells |
CHEMBL1124462 |
| HeLa |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in HeLa cells |
CHEMBL1124462 |
| Vero |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in african green monkey (Vero B) cells |
CHEMBL1124462 |
| ADMET |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce herpes simplex virus-1 (KOS)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| ADMET |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce herpes simplex virus-2 (G)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| Vaccinia virus |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| ADMET |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| HeLa |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cells |
CHEMBL1124462 |
| HeLa |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce polio virus -1 induced cytopathogenicity by 50% in HeLa cells |
CHEMBL1124462 |
| HeLa |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in HeLa cells |
CHEMBL1124462 |
| Vero |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| Sindbis virus |
MIC |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| Vero |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce parainfluenza virus-3 induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| Mammalian orthoreovirus 1 |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce reovirus-1 induced cytopathogenicity by 50% in african green monkey (VeroB)cells |
CHEMBL1124462 |
| Semliki forest virus |
MIC |
> |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce semliki forest virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| L1210 |
IC50 |
= |
0.018000000000000002 |
ug.mL-1 |
In vitro inhibition of L1210 (murine leukemia) cell growth. |
CHEMBL1122632 |
| L1210 |
IC50 |
= |
67.7 |
nM |
In vitro inhibition of L1210 (murine leukemia) cell growth. |
CHEMBL1122632 |
| Human herpesvirus 5 |
IC50 |
= |
500.0 |
nM |
Tested for antiviral activity against human cytomegalovirus by plaque assay |
CHEMBL1127034 |
| HFF |
IC50 |
= |
400.0 |
nM |
Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration |
CHEMBL1127034 |
| ADMET |
IC50 |
= |
1000.0 |
nM |
Tested for the inhibition against KB cell growth |
CHEMBL1127034 |
| L1210 |
IC50 |
= |
43.0 |
nM |
Tested for in vitro cell growth inhibition of L1210 cells |
CHEMBL1127034 |
| Homo sapiens |
IC50 |
= |
60.0 |
nM |
Tested for in vitro cell growth inhibition of H. Ep. 2 cells |
CHEMBL1127034 |
| CHO-K1-BH4 |
Inhibition |
= |
100.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the absence of S-9 microsome fraction at concentration 114*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
92.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the presence of S-9 microsome fraction at concentration 11.4*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
16.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the absence of S-9 microsome fraction at concentration 1.1*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
10.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the presence of S-9 microsome fraction at concentration 0.1*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
11.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the absence of S-9 microsome fraction at concentration 9 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
100.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the presence of S-9 microsome fraction at concentration 114*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
80.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the absence of S-9 microsome fraction at concentration 11.4*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
9.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the presence of S-9 microsome fraction at concentration 1.1*10e-4 micro M |
CHEMBL1128406 |
| CHO-K1-BH4 |
Inhibition |
= |
4.0 |
% |
Compound is tested for cytotoxicity in Chinese hamster ovary cells (CHO-K1-BH4) in the absence of S-9 microsome fraction at concentration 0.1*10e-4 micro M |
CHEMBL1128406 |
| Mus musculus |
grade |
= |
1.17 |
|
Compound is evaluated for the ability to inhibit the passive cutaneous anaphylaxis (PCA) reaction in mouse in presence of Ag |
CHEMBL1128406 |
| Human herpesvirus 1 |
MIC |
> |
0.2 |
ug.mL-1 |
Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Human herpesvirus 2 |
MIC |
= |
0.2 |
ug.mL-1 |
Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Vaccinia virus |
MIC |
> |
0.1 |
ug.mL-1 |
Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Vesicular stomatitis virus |
MIC |
= |
0.07 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Vesicular stomatitis virus |
MIC |
= |
0.07 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines, |
CHEMBL1126104 |
| Human poliovirus 1 |
MIC |
= |
0.2 |
ug.mL-1 |
Antiviral activity against polio virus type 1 in HeLa cell culture lines |
CHEMBL1126104 |
| Human coxsackievirus B4 |
MIC |
= |
0.2 |
ug.mL-1 |
Antiviral activity against coxsackie B4 virus in HeLa cell culture lines |
CHEMBL1126104 |
| Human coxsackievirus B4 |
MIC |
= |
0.07 |
ug.mL-1 |
Antiviral activity against coxsackie B4 in Vero cell culture lines |
CHEMBL1126104 |
| Human parainfluenza virus 3 |
MIC |
= |
0.02 |
ug.mL-1 |
Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines |
CHEMBL1126104 |
| Mammalian orthoreovirus 1 |
MIC |
= |
0.02 |
ug.mL-1 |
Antiviral activity against reovirus type 1 in Vero cell culture lines |
CHEMBL1126104 |
| Sindbis virus |
MIC |
> |
0.1 |
ug.mL-1 |
Antiviral activity against sindbis virus in Vero cell culture lines |
CHEMBL1126104 |
| Semliki forest virus |
MIC |
> |
0.1 |
ug.mL-1 |
Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines |
CHEMBL1126104 |
| Human herpesvirus 5 |
IC50 |
= |
500.0 |
nM |
Inhibitory concentration against human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1123999 |
| HFF |
IC50 |
= |
400.0 |
nM |
Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) |
CHEMBL1123999 |
| ADMET |
IC50 |
= |
600.0 |
nM |
Cytotoxicity against human neoplastic cell line(KB cells) |
CHEMBL1123999 |
| L1210 |
IC50 |
= |
43.0 |
nM |
Cytotoxicity in L1210 cell culture. |
CHEMBL1129959 |
| Homo sapiens |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| ADMET |
MIC |
= |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 1(KOS) in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| ADMET |
MIC |
= |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 2 (G) in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| Vaccinia virus |
MIC |
= |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against Vaccinia virus in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| Vesicular stomatitis virus |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration against Vesicular stomatitis virus in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| HeLa |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration in HeLa cell cultures |
CHEMBL1124622 |
| HeLa |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration against Vesicular stomatitis virus in HeLa cell cultures |
CHEMBL1124622 |
| HeLa |
MIC |
= |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration against Coxsackie virus B4 in HeLa cell cultures |
CHEMBL1124622 |
| HeLa |
MIC |
= |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration against polio virus 1 in HeLa cell cultures |
CHEMBL1124622 |
| Vero |
MCC |
= |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration in Vero cell cultures |
CHEMBL1124622 |
| Human parainfluenza virus 3 |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against parainfluenza 3 virus in Vero cell cultures |
CHEMBL1124622 |
| Mammalian orthoreovirus 1 |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against reovirus in Vero cell cultures |
CHEMBL1124622 |
| Sindbis virus |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration against Sindbis virus in Vero cell cultures |
CHEMBL1124622 |
| Human coxsackievirus B4 |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against Coxsackie virus B4 in Vero cell cultures |
CHEMBL1124622 |
| Semliki forest virus |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against forest virus in Vero cell cultures |
CHEMBL1124622 |
| ADMET |
MCC |
>= |
0.4 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in PRK cells. |
CHEMBL1123394 |
| HeLa |
MCC |
>= |
1.0 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in HeLa cells. |
CHEMBL1123394 |
| Vero |
MCC |
>= |
0.4 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in Vero B cells. |
CHEMBL1123394 |
| WI-38 |
MCC |
= |
0.4 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in Wi-38 cells. |
CHEMBL1123394 |
| ADMET |
MCC |
> |
0.1 |
ug.mL-1 |
Antiviral activity was measured against Herpes simplex virus (HSV-1 KOS) in rabbit kidney cells. |
CHEMBL1123394 |
| ADMET |
MCC |
> |
0.1 |
ug.mL-1 |
Antiviral activity was measured against Herpes simplex virus (HSV-2 G) in rabbit kidney cells. |
CHEMBL1123394 |
| ADMET |
MCC |
> |
0.1 |
ug.mL-1 |
Antiviral activity was measured against vaccinia virus in rabbit kidney cells. |
CHEMBL1123394 |
| ADMET |
MCC |
= |
0.07 |
ug.mL-1 |
Antiviral activity was measured against vesicular stomatitis virus in rabbit kidney cells. |
CHEMBL1123394 |
| HeLa |
MCC |
= |
0.07 |
ug.mL-1 |
Antiviral activity was measured against vesicular stomatitis virus in HeLa cells. |
CHEMBL1123394 |
| HeLa |
MCC |
= |
0.2 |
ug.mL-1 |
Antiviral activity was measured against polio virus-1 in HeLa cells. |
CHEMBL1123394 |
| HeLa |
MCC |
= |
0.2 |
ug.mL-1 |
Antiviral activity was measured against Coxsackie virus B4 in HeLa cells. |
CHEMBL1123394 |
| Vero |
MCC |
> |
0.1 |
ug.mL-1 |
Antiviral activity was measured against Coxsackie virus B4 in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
0.2 |
ug.mL-1 |
Antiviral activity was measured against Parainfluenza virus-3 in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
0.1 |
ug.mL-1 |
Antiviral activity was measured against Reo virus-1 in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
> |
0.1 |
ug.mL-1 |
Antiviral activity was measured against Sindbis virus in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
> |
0.4 |
ug.mL-1 |
Antiviral activity was measured against forest virus in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| WI-38 |
MCC |
= |
0.01 |
ug.mL-1 |
Antiviral activity was measured against Rhino virus-1A in human diploid (WI-38) cells. |
CHEMBL1123394 |
| WI-38 |
MCC |
= |
0.006999999999999999 |
ug.mL-1 |
Antiviral activity was measured against Rhino virus-9 in human diploid (WI-38) cells. |
CHEMBL1123394 |
| L1210 |
IC50 |
= |
40.0 |
nM |
In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells |
CHEMBL1124393 |
| Human herpesvirus 5 |
IC50 |
= |
500.0 |
nM |
Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV) |
CHEMBL1124393 |
| ADMET |
IC50 |
= |
300.0 |
nM |
Cytotoxicity was evaluated against the Human diploid cells (HFF) |
CHEMBL1124393 |
| ADMET |
IC50 |
= |
700.0 |
nM |
Cytotoxicity was evaluated in Human neoplastic cell line (KB) |
CHEMBL1124393 |
| ADMET |
MCC |
> |
1.0 |
ug.mL-1 |
Minimum cytotoxic concentration in primary rabbit kidney (PRK) cell cultures |
CHEMBL1124666 |
| Human herpesvirus 1 |
MIC |
> |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 1(KOS) |
CHEMBL1124666 |
| Human herpesvirus 2 |
MIC |
> |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 2(G) |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against Vaccinia virus |
CHEMBL1124666 |
| Vesicular stomatitis virus |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration against Vesicular stomatitis virus |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus in primary rabbit kidney cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
1.0 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus in HeLa cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus in Vero cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
0.1 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus embryonic skin muscle cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 1 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 1 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 2 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus embryonic skin muscle cell cultures |
CHEMBL1124666 |
| P388 |
ID50 |
= |
3.8 |
M |
Compound (1 x 10e-4 M) was evaluated in vitro for its ability to inhibit the growth of the murine leukemia P388 |
CHEMBL1124515 |
| L1210 |
ID50 |
= |
5.4 |
M |
Compound (1 x 10e-4 M) was evaluated in vitro for its ability to inhibit the growth of the murine leukemia L1210 |
CHEMBL1124515 |
| HL-60 |
ID50 |
= |
1.0 |
M |
Compound (1 x 10e-4 M) was evaluated in vitro for its ability to inhibit the growth of the human promyelocytic leukemia HL-60 |
CHEMBL1124515 |
| ADMET |
ID50 |
= |
5.2 |
M |
Compound (1 x 10e-4 M) was evaluated in vitro for its ability to inhibit the growth of the human epidermoid carcinoma KB |
CHEMBL1124515 |
| ADMET |
MCC |
= |
1.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with PRK cells |
CHEMBL1123770 |
| HeLa |
MCC |
> |
1.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with HeLa cells |
CHEMBL1123770 |
| Vero |
MCC |
> |
0.4 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with Vero B cells |
CHEMBL1123770 |
| WI-38 |
MCC |
> |
4.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with WI-38 cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
> |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against KOS strain of Herpes simplex virus-1 in primary rabbit kidney cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
> |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against G strain of Herpes simplex virus-2 in primary rabbit kidney cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vaccinia virus in primary rabbit kidney cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in primary rabbit kidney cells |
CHEMBL1123770 |
| HeLa |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in HeLa cells |
CHEMBL1123770 |
| HeLa |
MIC |
= |
0.07 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Polio virus-1 in HeLa cells |
CHEMBL1123770 |
| HeLa |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in HeLa cells |
CHEMBL1123770 |
| Vero |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Parainfluenza virus-3 in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
> |
0.1 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Reo virus-1 in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
= |
0.2 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Sindbis virus in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
> |
0.4 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against forest virus in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| WI-38 |
MIC |
= |
0.02 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus-1A in human diploid (WI-38)cells |
CHEMBL1123770 |
| WI-38 |
MIC |
> |
4.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus 9 in human diploid (WI-38)cells |
CHEMBL1123770 |
| L1210 |
Control |
= |
0.0 |
% |
In vitro antiproliferative effect against growth rate of L1210 cells at 100 uM concentration |
CHEMBL1126319 |
| L1210 |
IC50 |
= |
40.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated by determining their ability to inhibit growth of L1210 cells in vitro. |
CHEMBL1126319 |
| Homo sapiens |
Of control |
= |
0.0 |
% |
In vitro antiproliferative effect against growth rate of H. Ep.2 cells at 100 uM concentration |
CHEMBL1126319 |
| Homo sapiens |
IC50 |
= |
60.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated by determining their ability to inhibit growth of H.Ep.2 cells in vitro. |
CHEMBL1126319 |
| Human herpesvirus 5 |
IC50 |
= |
500.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using plaque reduction assay. |
CHEMBL1126319 |
| ADMET |
IC50 |
= |
400.0 |
nM |
Cytotoxicity of compound was determined visually in human diploid fibroblasts (HFF). |
CHEMBL1126319 |
| KB |
IC50 |
= |
1000.0 |
nM |
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). |
CHEMBL1126319 |
| Adenosine A1 receptor |
Ki |
> |
100000.0 |
nM |
Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand. |
CHEMBL1128285 |
| Adenosine A2a receptor |
Displacement |
= |
48.0 |
% |
Binding affinity determined on Adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand. |
CHEMBL1128285 |
| Adenosine A3 receptor |
Displacement |
= |
39.0 |
% |
Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat Adenosine A3 receptor |
CHEMBL1128285 |
| Unchecked |
MPR |
= |
0.071 |
|
Coronary vasoactivity as molar potency ratio (MPR), the quotient of ED50 of adenosine by that of the test nucleoside |
CHEMBL1122693 |
| Adenosine deaminase |
Ki |
|
|
nM |
Inhibition constant against calf intestinal adenosine deaminase; Not active |
CHEMBL1125631 |
| Adenosine kinase |
IC50 |
= |
10000.0 |
nM |
Inhibition of recombinant human adenosine kinase |
CHEMBL1133459 |
| Unchecked |
Km |
= |
9500.0 |
nM |
Activity of rabbit liver adenosine kinase |
CHEMBL1143932 |
| Unchecked |
Vmax |
= |
3.57 |
microM/min |
Activity of rabbit liver adenosine kinase |
CHEMBL1143932 |
| Unchecked |
Ki |
= |
500.0 |
nM |
Inhibition of rabbit liver adenosine kinase |
CHEMBL1143932 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Growth inhibition of mouse L2 cells at 37 uM |
CHEMBL1143932 |
| Unchecked |
Activity |
= |
114.0 |
|
Activity of rabbit liver adenosine kinase relative to adenosine |
CHEMBL1143932 |
| P388 |
Activity |
|
|
|
Cytotoxicity against mouse P388 cells |
CHEMBL1147386 |
| ADMET |
IC50 |
= |
1440.0 |
nM |
Cytotoxicity against human HeLaS3 cells after 7 hrs by celltiter-glo assay |
CHEMBL1269004 |
| ADMET |
IC50 |
= |
819.0 |
nM |
Cytotoxicity against human HeLaS3 cells after 24 hrs by celltiter-glo assay |
CHEMBL1269004 |
| ADMET |
IC50 |
= |
400.0 |
nM |
Cytotoxicity against human HeLaS3 cells after 48 hrs by celltiter-glo assay |
CHEMBL1269004 |
| Poliovirus |
IC50 |
= |
30.0 |
nM |
Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as inhibition of viral replication treated 1 hr before infection measured after 2 days |
CHEMBL1269004 |
| Dengue virus 2 |
IC50 |
|
|
|
Antiviral activity against Dengue virus type 2 in BHK-21 cells assessed as inhibition of viral replication after 24 hrs by luciferase assay |
CHEMBL1269004 |
| Unchecked |
EC50 |
= |
204.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based HTS Dose Confirmation to Identify Inhibitors of of 5'UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1813 (Primary HTS), 1827 (Project Summary)] |
CHEMBL1201862 |
| Unchecked |
EC50 |
< |
100.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of Luciferase Translation or Activity in H4 Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1813 (Primary HTS), 1827 (Project Summary)] |
CHEMBL1201862 |
| Unchecked |
EC50 |
= |
252.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response to Identify Inhibitors of Luciferase Translation or Activity in H4-C Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1813 (Primary HTS), 1827 (Project Summary)] |
CHEMBL1201862 |
| BJ |
EC50 |
= |
5044.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to BJ-TERT-LT-ST RAS-Independent Fibroblast. (Class of assay: confirmatory) [Related pubchem assays: 1674 (Project Summary), 1554 (Primary HTS)] |
CHEMBL1201862 |
| Nuclear receptor ROR-gamma |
Potency |
= |
1122.0 |
nM |
PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Heat shock factor protein 1 |
EC50 |
= |
3057.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Confirmation HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1). (Class of assay: confirmatory) [Related pubchem assays: 2118 (Project Summary), 2098 (Primary HTS)] |
CHEMBL1201862 |
| Unchecked |
IC50 |
= |
2438.0 |
nM |
PUBCHEM_BIOASSAY: High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
EC50 |
= |
4118.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to DRD Non-Viral Oncogenic Fibroblast. (Class of assay: confirmatory) [Related pubchem assays: 1674 (Project Summary), 1554 (Primary HTS)] |
CHEMBL1201862 |
| BJ |
EC50 |
= |
2082.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to BJ-TERT RAS-Independent Fibroblast. (Class of assay: confirmatory) [Related pubchem assays: 1674 (Project Summary), 1554 (Primary HTS)] |
CHEMBL1201862 |
| Nuclear receptor ROR-gamma |
Potency |
= |
631.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| BJ |
EC50 |
= |
5450.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to BJeLR RAS-Dependent Fibroblast. (Class of assay: confirmatory) [Related pubchem assays: 1674 (Project Summary), 1554 (Primary HTS)] |
CHEMBL1201862 |
| Unchecked |
EC50 |
= |
223.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response to Identify Inhibitors of 5'UTR Stem-Loop Driven Prion Protein mRNA Translation in H4-C Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1827 (Project Summary), 1813 (Primary HTS)] |
CHEMBL1201862 |
| Unchecked |
EC50 |
< |
100.0 |
nM |
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Confirmation HTS to Identify Inhibitors of of 5'UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1827 (Project Summary), 1813 (Primary HTS)] |
CHEMBL1201862 |
| Bacillus anthracis |
IC50 |
|
|
|
Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge |
CHEMBL1687814 |
| Bacillus anthracis |
IC50 |
|
|
|
Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs |
CHEMBL1687814 |
| J774.A1 |
Activity |
|
|
|
Cytotoxicity against mouse J774A1 cells |
CHEMBL1687814 |
| Unchecked |
Potency |
|
9200.0 |
nM |
PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504444] |
CHEMBL1201862 |
| Nuclear factor erythroid 2-related factor 2 |
Potency |
|
3662.6 |
nM |
PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] |
CHEMBL1201862 |
| Heat shock factor protein 1 |
AC50 |
= |
10488.0 |
nM |
PUBCHEM_BIOASSAY: HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_DoseNoFile_CherryPick_Activity_Set3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2118] |
CHEMBL1201862 |
| Unchecked |
IC50 |
= |
1010.0 |
nM |
PUBCHEM_BIOASSAY: Dose response confirmation of uHTS chemical inhibitors of both B-cell and T-cell specific antigen receptor-induced NF-kB activation in a 697B cell line using a luminescence assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435003, AID435022, AID465, AID489029] |
CHEMBL1201862 |
| Unchecked |
IC50 |
> |
80000.0 |
nM |
PUBCHEM_BIOASSAY: Dose response cytotoxicity of uHTS chemical inhibitors of both B-cell and T-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435003, AID435022, AID465, AID489020, AID489029] |
CHEMBL1201862 |
| Unchecked |
IC50 |
= |
7420.0 |
nM |
PUBCHEM_BIOASSAY: Dose response counterscreen of uHTS chemical inhibitors of both B-cell and T-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435003, AID435022, AID465, AID489019, AID489029] |
CHEMBL1201862 |
| Heat shock factor protein 1 |
AC50 |
= |
3174.0 |
nM |
PUBCHEM_BIOASSAY: HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_DoseNoFile_CherryPick_Internal-Standard_Set3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2118] |
CHEMBL1201862 |
| A549 |
GI50 |
= |
1.0 |
nM |
Cytostatic activity against human A549 cells after 5 days by SRB assay |
CHEMBL1811802 |
| NCI-H23 |
GI50 |
= |
11.0 |
nM |
Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay |
CHEMBL1811802 |
| DU-145 |
GI50 |
= |
18.0 |
nM |
Cytostatic activity against human DU145 cells after 5 days by SRB assay |
CHEMBL1811802 |
| PC-3 |
GI50 |
= |
48.0 |
nM |
Cytostatic activity against human PC3 cells after 5 days by SRB assay |
CHEMBL1811802 |
| HCT-116 |
GI50 |
= |
1.0 |
nM |
Cytostatic activity against human HCT116 cells after 5 days by SRB assay |
CHEMBL1811802 |
| HCT-15 |
GI50 |
= |
11.0 |
nM |
Cytostatic activity against human HCT15 cells after 5 days by SRB assay |
CHEMBL1811802 |
| Unchecked |
GI50 |
= |
98.0 |
nM |
Cytostatic activity against human Hs578 cells after 5 days by SRB assay |
CHEMBL1811802 |
| BT-549 |
GI50 |
|
|
|
Cytostatic activity against human BT549 cells after 5 days by SRB assay |
CHEMBL1811802 |
| MT4 |
GI50 |
= |
21.0 |
nM |
Cytostatic activity against human MT4 cells after 5 days by SRB assay |
CHEMBL1811802 |
| Jurkat |
IC50 |
= |
7830.0 |
nM |
PUBCHEM_BIOASSAY: Dose response confirmation of uHTS of chemical inhibitors of both B-cell and T-cell specific antigen receptor-induced NF-kB activation in a Jurkat cell line using a luminescence assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435003, AID435022, AID465, AID489029] |
CHEMBL1201862 |
| Chromobox protein homolog 1 |
Potency |
|
11220.2 |
nM |
PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] |
CHEMBL1201862 |
| DNA polymerase iota |
Potency |
|
100000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] |
CHEMBL1201862 |
| HepG2 |
Potency |
|
1000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
316.2 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of Cell Surface uPA Generation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493178] |
CHEMBL1201862 |
| Mothers against decapentaplegic homolog 3 |
Potency |
|
446.7 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] |
CHEMBL1201862 |
| BJ |
EC50 |
< |
104.0 |
nM |
PUBCHEM_BIOASSAY: Fluorescence Cell-Based Dose Response to Characterize Compounds Cytotoxic to RAS-Dependent BJ-TERT-LT-ST Fibroblast. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1554, AID1674] |
CHEMBL1201862 |
| HEK293 |
Activity |
> |
2.5 |
uM |
Cytotoxicity against human HEK293 cells |
CHEMBL1909608 |
| Programmed cell death protein 4 |
max activation |
= |
94.2 |
% |
Stabilization of Pdcd4 expressed in TPA-stimulated human HEK293 cells at 2.5 uM by luciferase reporter assay |
CHEMBL1909608 |
| Programmed cell death protein 4 |
IC50 |
= |
880.0 |
nM |
Stabilization of Pdcd4 expressed in human HEK293 cells assessed as inhibition of TPA-induced degradation by luciferase reporter assay |
CHEMBL1909608 |
| Geminin |
Potency |
|
517.4 |
nM |
PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1584.9 |
nM |
PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
35481.3 |
nM |
PubChem BioAssay. qHTS Assay for Inhibitors of Hepatitis C Virus (HCV). (Class of assay: confirmatory) |
CHEMBL1201862 |
| Geminin |
Potency |
|
651.3 |
nM |
PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Ataxin-2 |
Potency |
|
3162.3 |
nM |
PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Glucagon-like peptide 1 receptor |
Potency |
|
1584.9 |
nM |
PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) |
CHEMBL1201862 |
| Acetylcholinesterase |
Inhibition |
= |
4.48 |
% |
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method |
CHEMBL2163249 |
| Cholinesterase |
Inhibition |
= |
-12.3 |
% |
Inhibition of horse BChE at 2 mg/ml by Ellman's method |
CHEMBL2163249 |
| Unchecked |
Potency |
|
819.9 |
nM |
PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
145.8 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
20.6 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Isocitrate dehydrogenase [NADP] cytoplasmic |
Potency |
|
651.3 |
nM |
PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1412.5 |
nM |
PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
= |
2770.0 |
nM |
PubChem BioAssay. Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition Measured in Cell-Based System Using Plate Reader - 7011-01_Antagonist_Dose_CherryPick_Activity_Set2. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Mothers against decapentaplegic homolog 3 |
Potency |
|
819.9 |
nM |
PubChem BioAssay. qHTS for Inhibitors of TGF-b: CCL64 Cells Orthogonal Assay for Cherry Picks. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
AC50 |
= |
91.2 |
nM |
PubChem BioAssay. A549 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-06_Antagonist_Dose_CherryPick_Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
AC50 |
= |
250.0 |
nM |
PubChem BioAssay. HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Antagonist_Dose_CherryPick_Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
920.0 |
nM |
PubChem BioAssay. qHTS for Inhibitors of TGF-b: Cytotox Counterscreen for Cherry Picks. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
2511.9 |
nM |
PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
= |
3980.0 |
nM |
PubChem BioAssay. LGR2:Counterscreen with MC4R Measured in Cell-Based System Using Plate Reader - 7011-02_Antagonist_Dose_CherryPick_Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Parathyroid hormone receptor |
Potency |
|
35481.3 |
nM |
PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Mothers against decapentaplegic homolog 3 |
Potency |
|
580.5 |
nM |
PubChem BioAssay. qHTS for Inhibitors of TGF-b: Confirmation of Cherry Picks. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1778.3 |
nM |
PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
AC50 |
= |
1600.0 |
nM |
PubChem BioAssay. HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-01_Antagonist_Dose_CherryPick_Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
819.9 |
nM |
PubChem BioAssay. Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Mothers against decapentaplegic homolog 3 |
Potency |
|
9200.0 |
nM |
PubChem BioAssay. qHTS for Inhibitors of TGF-b: Hit Validation in HepG2 Cells using COP promoter. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Guanine nucleotide-binding protein G(s), subunit alpha |
Potency |
|
25118.9 |
nM |
PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1412.5 |
nM |
PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Nuclear factor erythroid 2-related factor 2 |
Potency |
|
651.3 |
nM |
PubChem BioAssay. Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
28183.8 |
nM |
PubChem BioAssay. High Throughput Screening for Foot and Mouth Disease Virus Antivirals. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Heat shock cognate 71 kDa protein |
Kd |
= |
28183.83 |
nM |
Binding affinity to human truncated HSC70 NBD (1 to 381 residues) by SPR analysis |
CHEMBL3822412 |
| Heat shock cognate 71 kDa protein |
Kd |
= |
28000.0 |
nM |
Binding affinity to human truncated HSC70 NBD (1 to 381 residues) by SPR analysis |
CHEMBL3822412 |
| NS5 |
EC50 |
= |
1300.0 |
nM |
Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by measuring reduction in virus-induced cytopathic effect after 5 days by MTS assay |
CHEMBL4354808 |
| NS5 |
EC50 |
= |
1300.0 |
nM |
Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by measuring reduction in virus-yield |
CHEMBL4354808 |
| NS5 |
EC50 |
= |
1300.0 |
nM |
Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by methylene blue staining based by Plaque reduction assay |
CHEMBL4354808 |
| NS5 |
EC50 |
= |
1300.0 |
nM |
Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by Alexa Fluor 488/DAPI staining based assay |
CHEMBL4354808 |
| Vero |
CC50 |
> |
357000.0 |
nM |
Cytotoxicity against African green monkey Vero cells by visual method |
CHEMBL4354808 |
| Plasmodium falciparum |
IC37 |
= |
0.7 |
uM |
Antimalarial activity against Plasmodium falciparum FCQ-27 isolate infected in erythrocytes assessed as reduction in [G-3H]Hypoxanthine incorporation incubated for 24 hrs followed by addition of [G-3H]Hypoxanthine and measured after 18 to 20 hrs by scintillation counting method |
CHEMBL4376805 |
| Trypanosoma brucei brucei |
EC50 |
= |
480.0 |
nM |
Antitrypanosomal activity against Trypanosoma brucei brucei Squib 427 after 48 hrs by alamar blue assay |
CHEMBL4422651 |
| Trypanosoma brucei rhodesiense |
EC50 |
|
|
|
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB-900 after 48 hrs by alamar blue assay |
CHEMBL4422651 |
| Unchecked |
Ratio EC50 |
= |
4.6 |
|
Selectivity index, ratio of EC50 for human MRC5 cells to EC50 for Trypanosoma brucei brucei Squib 427 |
CHEMBL4422651 |
| MRC5 |
EC50 |
= |
2230.0 |
nM |
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye-based assay |
CHEMBL4422651 |
| Unchecked |
Ratio EC50 |
|
|
|
Selectivity index, ratio of EC50 for human MRC5 cells to EC50 for Trypanosoma brucei rhodesiense STIB-900 |
CHEMBL4422651 |
| Trypanosoma brucei |
EC50 |
= |
150.0 |
nM |
Antitrypanosomal activity against wild type Trypanosoma brucei Lister 427 after 48 hrs by alamar blue assay |
CHEMBL4422651 |
| Trypanosoma brucei |
EC50 |
= |
2610.0 |
nM |
Antitrypanosomal activity against Trypanosoma brucei TbAT1-KO after 48 hrs by alamar blue assay |
CHEMBL4422651 |
| Trypanosoma brucei |
EC50 |
= |
4300.0 |
nM |
Antitrypanosomal activity against pentamidine/diminazene/melaminophenyl arsenical resistant Trypanosoma brucei B48 after 48 hrs by alamar blue assay |
CHEMBL4422651 |
| Trypanosoma brucei |
EC50 |
= |
1700.0 |
nM |
Antitrypanosomal activity against isometamidium resistant Trypanosoma brucei ISMR1 after 48 hrs by alamar blue assay |
CHEMBL4422651 |
| Trypanosoma brucei |
Ratio EC50 |
= |
17.2 |
|
Resistance factor, ratio of EC50 for Trypanosoma brucei TbAT1-KO to EC50 for wild type Trypanosoma brucei Lister 427 |
CHEMBL4422651 |
| Trypanosoma brucei |
Ratio EC50 |
= |
28.7 |
|
Resistance factor, ratio of EC50 for pentamidine/diminazene/melaminophenyl arsenical resistant Trypanosoma brucei B48 to EC50 for wild type Trypanosoma brucei Lister 427 |
CHEMBL4422651 |
| Trypanosoma brucei |
Ratio EC50 |
= |
11.1 |
|
Resistance factor, ratio of EC50 for isometamidium resistant Trypanosoma brucei B48 to EC50 for wild type Trypanosoma brucei Lister 427 |
CHEMBL4422651 |
| Trypanosoma cruzi |
EC50 |
= |
340.0 |
nM |
Antitrypanosomal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 harboring beta-galactosidase infected in human MRC5 cells after 7 days by resazurin dye-based assay |
CHEMBL4422651 |
| Unchecked |
Ratio EC50 |
= |
6.5 |
|
Selectivity index, ratio of EC50 for human MRC5 cells to EC50 for nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 harboring beta-galactosidase |
CHEMBL4422651 |
| Unchecked |
Ki |
= |
78000.0 |
nM |
Inhibition of [3H]-adenosine transport at Trypanosoma brucei Adenosine transporter P1 expressed in pentamidine/diminazene/melaminophenyl arsenical resistant Trypanosoma brucei B48 bloodstream forms after 60 secs by scintillation counting analysis |
CHEMBL4422651 |
| Unchecked |
Ki |
= |
3800.0 |
nM |
Inhibition of [3H]-adenosine transport at Trypanosoma brucei Adenosine transporter P2 expressed in pentamidine/diminazene/melaminophenyl arsenical resistant Trypanosoma brucei B48 bloodstream forms after 60 secs by scintillation counting analysis |
CHEMBL4422651 |
| Peritoneal macrophage cells |
Activity |
|
|
|
Cytotoxicity against Swiss mouse primary peritoneal macrophages assessed as reduction in cell viability after 5 days |
CHEMBL4422651 |
| Leishmania infantum |
EC50 |
= |
130.0 |
nM |
Antileishmanial activity against Leishmania infantum amastigotes infected in Swiss mouse primary peritoneal macrophages assessed as reduction in parasite burden after 5 days by Giemsa staining-based microscopic analysis |
CHEMBL4422651 |
| Trypanosoma congolense |
EC50 |
|
|
|
Antitrypanosomal activity against Trypanosoma congolense by resazurin assay |
CHEMBL4422651 |
| Histone-lysine N-methyltransferase, H3 lysine-79 specific |
Inhibition |
= |
41.0 |
% |
Inhibition of DOT1L (unknown origin) at 200 uM using chicken nucleosome as substrate in presence of [3H]SAM incubated for 1 hr by TopCount method |
CHEMBL4477246 |
| SARS-CoV-2 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
19952.62 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| Unchecked |
Ki |
= |
78000.0 |
nM |
Inhibition of Trypanosoma brucei P1 transporter assessed as reduction in [3H]-adenosine uptake by scintillation counting method |
CHEMBL4680158 |
| Unchecked |
Ki |
= |
3800.0 |
nM |
Inhibition of Trypanosoma brucei P2 transporter assessed as reduction in [3H]-adenosine uptake by scintillation counting method |
CHEMBL4680158 |
| A549 |
IC50 |
= |
44.0 |
nM |
Cytotoxicity against human A549 cells assessed as cell growth inhibition |
CHEMBL4699613 |
| HCT-116 |
IC50 |
= |
82.0 |
nM |
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition |
CHEMBL4699613 |
| A-375 |
IC50 |
= |
43.0 |
nM |
Cytotoxicity against human A-375 cells assessed as cell growth inhibition |
CHEMBL4699613 |
| SK-OV-3 |
IC50 |
= |
131.0 |
nM |
Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition |
CHEMBL4699613 |
| PC-3 |
IC50 |
= |
76.0 |
nM |
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition |
CHEMBL4699613 |
| DU-145 |
IC50 |
= |
256.0 |
nM |
Cytotoxicity against human DU-145 cells assessed as cell growth inhibition |
CHEMBL4699613 |
| T47D |
IC50 |
= |
13.0 |
nM |
Cytotoxicity against human T47D cells assessed as cell growth inhibition |
CHEMBL4699613 |
| HFF |
IC50 |
= |
790.0 |
nM |
Cytotoxicity against human HFF cells assessed as cell growth inhibition |
CHEMBL4699613 |
| Trypanosoma brucei rhodesiense |
EC50 |
= |
36.0 |
nM |
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 measured after 6 hrs by alamar blue dye based fluorimetry analysis |
CHEMBL4811241 |
| Trypanosoma brucei rhodesiense |
EC50 |
= |
36.0 |
nM |
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 incubated for 48 hrs by resazurin dye based fluorescence assay |
CHEMBL4813968 |
| MRC5 |
CC50 |
= |
2230.0 |
nM |
Cytotoxicity against human MRC5 fibroblast cells assessed as reduction in cell viability measured after 3 days by fluorometry |
CHEMBL5131491 |
| Trypanosoma cruzi |
EC50 |
= |
340.0 |
nM |
Antitrypanosomal activity against intracellular Trypanosoma cruzi Tulahuen amastigotes expressing CL2 beta-galactosidase in human MRC5 cells assessed as parasite growth inhibition using chlorophenol red beta-D-galactopyranoside as substrate treated for 7 days by spectrophotometry |
CHEMBL5131491 |
| ADMET |
Selectivity Index |
= |
6.6 |
|
Selectivity index, ratio of CC50 for human MRC-5 cells to EC50 for antitrypanosomal activity against intracellular Trypanosoma cruzi Tulahuen amastigotes expressing CL2 beta-galactosidase in human MRC5 cells |
CHEMBL5131491 |
| Leishmania infantum |
EC50 |
= |
130.0 |
nM |
Antileishmanial activity against intracellular Leishmania infantum MHOM/MA(BE)/67 amastigotes infected in Swiss mouse peritoneal macrophages assessed as parasite growth inhibition incubated for 5 days by giemsa staining based microscopic analysis |
CHEMBL5131491 |
| Macrophages |
CC50 |
= |
130.0 |
nM |
Cytotoxicity against Swiss mouse peritoneal macrophages assessed as reduction in cell viability measured after 5 days by microscopic analysis |
CHEMBL5131491 |
| ADMET |
Selectivity Index |
= |
1.0 |
|
Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to EC50 for antileishmanial activity against intracellular Leishmania infantum MHOM/MA(BE)/67 amastigotes infected in Swiss mouse peritoneal macrophages |
CHEMBL5131491 |
